Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.34 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.34 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.34 |
| ▸ | ALB | P02768 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27706788 | 0.85 | KCNH2 (0.36) | KCNH2HDAC6APP | |
| SCHEMBL24198823 | 0.85 | PDE10A (0.36) | GABRA1GABRB2FAAH | |
| SCHEMBL8252283 | 0.81 | GBA1 (0.53) | — | |
| SCHEMBL18924320 | 0.81 | KCNH2 (0.34) | KCNH2HDAC6APP | |
| SCHEMBL805514 | 0.78 | KDM4E (0.43) | KCNH2HDAC6APPTSHR | |
| SCHEMBL18858527 | 0.78 | ESR1 (0.42) | GABRA1GABRB2FAAHPTGS1PTGS2 | |
| SCHEMBL17229265 | 0.77 | SMN1; SMN2 (0.43) | LMNA | |
| SCHEMBL13428866 | 0.77 | CD274 (0.40) | KCNH2HDAC6APP | |
| SCHEMBL26240013 | 0.76 | KCNH2 (0.31) | KCNH2HDAC6 | |
| SCHEMBL1569639 | 0.76 | HDAC6 (0.40) | KCNH2HDAC6APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| WO-2023016529-A1 | NAPHTHYRIDINE DERIVATIVE AS ATR INHIBITOR AND METHOD FOR PREPARING SAME | 微境生物医药科技(上海)有限公司 | 2023-02-16 | — | — | WO | disclosed |
| US-11059826-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2019-10-24 | — | — | US | disclosed |
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
| US-7300936-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | APP, APBA1, BACE1 | KCNH2 4064/4885HDAC6 2460/4885GABRA1 1419/4885 |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | KCNH2 4273/4885HDAC6 1925/4885GABRA1 3502/4885 |
| US-11059826-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | KCNH2 4273/4885HDAC6 1925/4885GABRA1 3502/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | KCNH2 4273/4885HDAC6 1925/4885GABRA1 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.